Dr. Shore on Future Clinical Research Focuses in Prostate Cancer

Neal Shore MD, FACS, U.S. chief medical officer of Surgery and Oncology, GenesisCare, director, CPI, Carolina Urologic Research Center, discusses future clinical research focuses in prostate cancer.

Although significant research has been conducted with PARP inhibitors for patients with castration-resistant prostate cancer (CRPC), additional efforts are underway to evaluate the agents in castration-sensitive prostate cancer (CSPC), Shore says. These research efforts focus include patients with newly diagnosed metastatic CSPC and de novo disease, Shore adds. Although these ongoing and future studies tend to be biomarker dependent for enrollment, some still feature an all-comer population, Shore explains.

Another area of interest is the evaluation of combination therapies in patients with prostate cancer, Shore continues. These combinations can include PARP inhibition with established radiopharmaceuticals, such as radium-223, to exploit double-stranded DNA breaks, Shore concludes.